GARDASIL® [Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine] | GARDASIL Quadrivalent Human Papillomavirus Types 6 11 16 18 Recombinant Vaccine GARDASIL is a registered trademark of Merck Co. Inc. GARDASIL Quadrivalent Human Papillomavirus Types 6 11 16 18 Recombinant Vaccine Estimated Annual Burden of Human Papillomavirus HPV -Related Diagnoses in the United States 9 710 new cases of cervical cancer1 330 000 new cases of high-grade cervical dysplasia CIN 2 3 2 million new cases of low-grade cervical dysplasia CIN 1 2 1 million new cases of genital warts3 CIN cervical intraepithelial neoplasia. 1. American Cancer Society. Cancer Facts and Figures 2006. American Cancer Society 2006 4. 2. Schiffman M et al. Arch Pathol Lab Med. 2003 127 946-949. 3. Fleischer AB et al. Sex Transm Dis. 2001 28 643-647. 2 GARDASIL Quadrivalent Human Papillomavirus Types 6 11 16 18 Recombinant Vaccine Targeting a High Disease Burden With GARDASIL HPV Type Approximate Disease Burden 16 and 18 70 of cervical cancer AIS CIN 3 VIN 2 3 and ValN 2 3 cases 50 of CIN 2 cases 6 11 16 and 18 35 -50 of all CIN 1 VIN 1 and VaIN 1 cases 90 of genital warts cases AIS adenocarcinoma in situ. VIN vulvar intraepithelial neoplasia. ValN vaginal intraepithelial neoplasia.
